Status:
COMPLETED
New-diagnosed PCNSL Treated With Methotrexate (MTX) and Orelabrutinib-based Regimen
Lead Sponsor:
Huashan Hospital
Conditions:
Primary Central Nervous System Lymphoma
Eligibility:
All Genders
18-75 years
Brief Summary
This study was a single-centre, retrospective study that retrospectively collected first-line PCNSL patients receiving methotrexate-based chemotherapy ± orelabrutinib at Huashan Hospital of Fudan Univ...
Detailed Description
The study was divided into two retrospective cohorts of approximately 35-40 patients each. Cohort A was the cohort of patients who received methotrexate-based chemotherapy alone, and cohort B was the ...
Eligibility Criteria
Inclusion
- Pathologically confirmed primary central nervous system lymphoma
- Methotrexate-based chemotherapy ± orelabrutinib regimen as first-line treatment for patients
Exclusion
- Patients receiving ≤2 cycles of treatment without efficacy evaluation
- Those with uncontrolled or significant cardiovascular disease, including: uncontrolled diabetes mellitus, severe cardiac, pulmonary, hepatic, renal insufficiency) and haematological, endocrine system lesions, history of other uncontrollable malignancies
Key Trial Info
Start Date :
August 10 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 30 2024
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT06115824
Start Date
August 10 2023
End Date
July 30 2024
Last Update
September 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hematology, Huashan Hospital, Fudan University
Shanghai, China